Neurosense Therapeutics Ltd（NRSN）の財務NRSNNeurosense Therapeutics Ltd

In the context of the broader market, NRSN competes directly with industry leaders such as ERNA and KALA. With a market capitalization of $3.04M, it holds a significant position in the sector. When comparing efficiency, NRSN's gross margin of N/A stands against ERNA's N/A and KALA's N/A. Such benchmarking helps identify whether Neurosense Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

Neurosense has reported consistent net losses, with a net income of -3.56 million in the first half of 2026, indicating ongoing financial struggles. The current ratio has dropped to 0.28, highlighting liquidity issues.